Sociedad Americana de Hirudoterapia

Heparin-induced thrombocytopenia in the pediatric population: a review of current literature

Review published in J Pediatr Pharmacol Ther (2012)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDesarrollo de fármacosEnsayos clínicosVakil NH et al. · The journal of pediatric pharmacology and therapeutics, 2012

Abstract

Heparin-induced thrombocytopenia is a rare and serious reaction to unfractionated heparin and low-molecular-weight heparins in children. Quick recognition, discontinuation of heparin, and subsequent treatment with an alternative anticoagulant are essential steps to prevent serious complications such as thrombus and limb amputation. The purpose of this review is to describe the clinical features of heparin-induced thrombocytopenia in children and to summarize the data available for its management. This paper summarizes data and relates the use of direct thrombin inhibitors with clinical outcomes. A literature search was conducted with Ovid, using the key terms argatroban, bivalirudin, hirulog, danaparoid, lepirudin, direct thrombin inhibitor, heparin-induced thrombocytopenia, thrombosis, warfarin, and fondaparinux. Articles were excluded if they were classified as editorials, review articles, or conference abstracts or if they involved patients 18 years of age or older or described disease states not related to thrombosis. Nineteen articles containing 33 case reports were identified and evaluated for this review. Of the 33 cases, 14, 10, 4, and 2 cases described the use of lepirudin, danaparoid, argatroban, and bivalirudin, respectively. Two cases did not report the type of anticoagulant used, and 1 case used aspirin. The most commonly reported complication was bleeding.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

Review of 33 pediatric HIT case reports across 19 articles; lepirudin used in 14 cases, danaparoid in 10, argatroban in 4 and bivalirudin in 2, all leech-derived DTIs feature prominently.

Por qué esto importa para la hirudoterapia

This review summarizes clinical features and management data for heparin-induced thrombocytopenia (HIT) in the pediatric population, identifying 33 case reports across nineteen articles and evaluating alternative anticoagulants including direct thrombin inhibitors. Of the 33 cases, lepirudin was the most frequently reported agent (14 cases), followed by danaparoid (10), argatroban (4), and bivalirudin (2), with bleeding as the most commonly reported complication. While lepirudin appears prominently in this pediatric case series, the abstract does not describe its origin, mechanism, or any connection to leeches or hirudotherapy. No defensible leech link can be drawn from the abstract alone; the article is focused on HIT management in children.

Citación

Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.

Vakil NH et al. · The journal of pediatric pharmacology and therapeutics, 2012

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.